Salesforce.com to B...
Health Care: Drugs
Achillion Pharmaceuticals Inc. (ACHN: NASDAQ)
$6.95 0.06 | 0.87%
06/04/12 - 02:38 PM ET
Company Income Statement
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Sales | 247.00K | 2.44M | -294.00K | -234.00K |
| Cost of Sales | -805.00K | -940.00K | -1.11M | -508.00K |
| Gross Operating Profit | 1.05M | 3.38M | 818.00K | 274.00K |
| Selling, General, and Administrative Expenses | 9.15M | 7.20M | 6.55M | 6.55M |
| Research & Development | 35.44M | 20.53M | 18.42M | 21.15M |
| Operating Income before D & A (EBITDA) | -43.54M | -24.36M | -24.15M | -27.42M |
| Depreciation & Amortization | 805.00K | 940.00K | 1.11M | 508.00K |
| Interest Income | 186.00K | 101.00K | 172.00K | 707.00K |
| Other Income - Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -44.16M | -25.20M | -25.37M | -27.22M |
| Interest Expense | 45.00K | 284.00K | 564.00K | 1.06M |
| Pre-Tax Income | -44.21M | -25.48M | -25.93M | -28.28M |
| Income Taxes | 0.00 | 0.00 | 0.00 | -132.00K |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -44.21M | -25.48M | -25.93M | -28.15M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -44.21M | -25.48M | -25.93M | -28.15M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -44.21M | -25.48M | -25.93M | -28.15M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-44.21M | -25.48M | -25.66M | -28.15M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -44.21M | -25.48M | -25.93M | -28.15M |
| Basic EPS from Continuing Ops. | -0.69 | -0.57 | -0.98 | -1.42 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.69 | -0.57 | -0.98 | -1.42 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.69 | -0.57 | -0.98 | -1.42 |
| Basic Normalized Net Income/Share | -0.69 | -0.57 | -0.97 | -1.42 |
| EPS fr Continuing Ops. | -0.69 | -0.57 | -0.98 | -1.42 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.69 | -0.57 | -0.98 | -1.42 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.69 | -0.57 | -0.98 | -1.42 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.69 | -0.57 | -0.97 | -1.42 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with ACHN
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- UserThe cash burners
- ContributorStocks Under-$10 Moving Hig...
- Contributor10 Hep C Stocks on Wall Str...
- Contributor10 Health-Care Stocks Outpe...
- ContributorHep C Drug Stocks in the Sp...
- UserStocks Under $5
- UserLegal Tender II
- UserTop Picks Under $5 for 2011...
- ContributorTop Stock Picks Under $5 fo...
Latest ACHN Headlines from TheStreet
- Grading Hep C Stocks Exiting EASL Confab 04.23.12 | 09:04 am
- Achillion Stock Gaps Down On Today's Open (ACHN) 04.19.12 | 08:04 am
- For Biotech, 'Fail' is Making a Big Comeback 03.12.12 | 08:03 am
- 8 Stocks Rising on Monster Volume 02.17.12 | 02:02 pm
- Hedge Funds Catch Hep C Fever 02.15.12 | 10:02 am
- Biotech Stock Mailbag: Vical, Hep C Drugs 01.27.12 | 07:01 am
- BioLineRx: Tuesday's Hot Hep C Drug Stock 01.24.12 | 11:01 am
- Idenix Pharma Buyout Likely: Survey 01.20.12 | 03:01 pm
- Biotech Stock Mailbag: Celldex, Hep C Bubble, Al Mann Anger 01.20.12 | 05:01 am
- 4 Companies That Are Bleeding Cash 01.13.12 | 07:01 am
Press Releases for ACHN
- Emerald Holds Annual Groundhog Day Investment Forum - Business Wire 02.06.12 | 08:02 am
Partner Headlines for ACHN
- Achillion Announces 94 - 100% Complete EVR From Phase 2 Trial With ACH-1625 Based Regimen in Hepatitis C - Benzinga 04.21.12 | 04:04 pm
- UPDATE: Bank of America Raises Actuant's PT - Benzinga 03.08.12 | 01:03 pm
- Gilead's Electron Data Brings Some Reality Back To The Hep C Market - Seeking Alpha 02.17.12 | 09:02 am
- 10 Biotech Stocks With 100% Upside In 2012: Part One - Seeking Alpha 02.09.12 | 10:02 am
- Company News for January 25, 2012 - Corporate Summary - Zacks 01.25.12 | 10:01 am
- Afternoon Movers; Negative Euro News - Benzinga 01.24.12 | 04:01 pm
- Benzinga's M&A Chatter for Friday January 20, 2012 - Benzinga 01.20.12 | 06:01 pm
- End-of-Day Market Summary for January 20, 2012 - Benzinga 01.20.12 | 04:01 pm
- Afternoon Movers; Markets Moved Sideways - Benzinga 01.20.12 | 04:01 pm
- 10 Biotech Stocks With Strong Corporate Governance - Seeking Alpha 01.18.12 | 09:01 am
